Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder
- 17 December 2023
- journal article
- research article
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 255, 111063
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Lorcaserin, a selective 5-HT 2C receptor agonist, decreases alcohol intake in female alcohol preferring ratsPharmacology Biochemistry and Behavior, 2014
- The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination, and Reinstatement: Relationship to Feeding Behavior and Impulse ControlNeuropsychopharmacology, 2011
- Lorcaserin, a 5-HT2C Agonist, Decreases Nicotine Self-Administration in Female RatsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cuesNeuropharmacology, 2011
- Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical TrialsAlcohol, Clinical and Experimental Research, 2010
- Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity IndexDrug and Alcohol Dependence, 2007
- Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmissionPharmacology & Therapeutics, 2007
- Measuring Outcome in Interventions for Alcohol Dependence and Problem Drinking: Executive Summary of a Conference Sponsored by the National Institute on Alcohol Abuse and AlcoholismAlcohol, Clinical and Experimental Research, 2003
- The Measurement of CravingJournal of Addictive Diseases, 2001
- Contrast of Treatment-Seeking and Untreated Cocaine AbusersArchives of General Psychiatry, 1992